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ABSTRACT
Serious infections caused by bacteria that have become resistant to commonly used 
antibiotics have become a major global healthcare problem in the 21st century. 
Antibiotic resistance, initially a problem of the hospital setting associated with an 
increased number of hospitals acquired infections usually in critically ill and 
immuno-suppressed patients, has now extended into the community causing severe 
infections difficult to diagnose and treat. In hospitals, most common resistant 
bacteria include methicillin-resistant Staphylococcus aureus, vancomycin-resistant 
enterococci and gram-negative rods including Enterobacteriaceae and Pseudomonas 
aeruginosa. Vancomycin intermediate and resistant S. aureus, represent a new 
treatment challenge. In the community, penicillin and macrolide-resistant 
pneumococci developed several decades ago and are now present all over the world. 
More recently, community-acquired methicillin-resistant S. aureus has become a 
problem in several countries causing skin infections but also severe diseases. The 
molecular mechanisms by which bacteria have become resistant to antibiotics are 
diverse and complex. Bacteria have developed resistance to all different classes of 
antibiotics discovered to date. The most frequent type of resistance is acquired and 
transmitted horizontally via the conjugation of a plasmid. In recent times new 
mechanisms of resistance have resulted in the simultaneous development of 
resistance to several antibiotic classes creating very dangerous multidrug-resistant 
(MDR) bacterial strains, some also known as ‘‘superbugs’’. In many cases the use of 
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antibiotics is unnecessary or questionable. The indiscriminate and inappropriate use 
of antibiotics in outpatient clinics, hospitalized patients and in the food industry is 
the single largest factor leading to antibiotic resistance. In recent years, the number 
of new antibiotics licensed for human use in different parts of the world has been 
lower than in the recent past. In addition, there has been less innovation in the field 
of antimicrobial discovery research and development. The pharmaceutical industry, 
large academic institutions or the government are not investing the necessary 
resources to produce the next generation of newer safe and effective antimicrobial 
drugs. In many cases, large pharmaceutical companies have terminated their anti-
infective research programs altogether due to economic reasons. The potential 
negative consequences of all these events are relevant because they put society at 
risk for the spread of potentially serious MDR bacterial infections.
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1. INTRODUCTION
The term "antibiotic" originally referred to a natural compound produced by a 
fungus or another microorganism that kills bacteria, which cause disease in humans 
or animals. Some antibiotics may be synthetic compounds (not produced by 
microorganisms) that can also kill or inhibit the growth of microbes. Technically, the 
term "Antibiotic" refers to synthetic compounds as well as natural compounds, and 
to refer to antiviral as well as antibacterial drugs. 
The first antibiotic, penicillin, was discovered in 1929 by Sir Alexander Fleming 
who observed inhibition of staphylococci on an agar plate contaminated by a 
Penicillium mold. In World War II the inevitable bacterial infections that occurred in 
war-related wounds was an important impetus to study the chemotherapeutic value 
of penicillin. Penicillin became generally available for treatment of bacterial 
infections, especially those caused by staphylococci and streptococci, about 1946. 
Initially, penicillin was effective against all sorts of infections caused by these two 
gram-positive bacteria. A significant fraction of all human infections are caused by 
these two bacteria (i.e., strep throat, pneumonia, septicemia, skin infections, wound 
infections, scarlet fever, toxic shock syndrome). Penicillin had unbelievable ability to 
kill these bacterial pathogens without harming the host that harbored them. 
Resistance to penicillin in some strains of staphylococci was recognized almost 
immediately after introduction of the drug. Surprisingly, Streptococcus pyogenes
(Group A strep) have never fully developed resistance to penicillin and it remains a 
reasonable choice antibiotic for many types of streptococcal infections. Interestingly, 
penicillin has never been effective against most gram-negative pathogens (e.g. 
Salmonella, Shigella, Bordetella pertussis, Yersinia pestis, Pseudomonas) with the notable 
exception of Neisseria gonorrhoeae. 
The list of bacteria developing resistance is impressive, from sulfonamide and 
penicillin-resistant Staphylococcus aureus in the 1930s and 1940s (Levy, 2002; 
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Rammelkamp, 1942) to penicillin-resistant Neisseria gonorrhoeae (PPNG), and β-
lactamase-producing Haemophilus influenzae in the 1970s, (Jaffe et al., 1981; Lind, 1990; 
Williams and Moosdeen, 1986; Jorgensen, 1993) methicillin resistant Staphylococcus
aureus (MRSA) and the resurgence of multi-drug resistant (MDR) Mycobacterium
tuberculosis in the late 1970s and 1980s, (Lowy, 1998; Deresinski, 2005; Lowy, 2003; 
Foster, 2004; Pablos-Mendez et al., 1998; Espinal et al., 2001) and several resistant 
strains of common enteric and non-enteric gram-negative bacteria such as Shigella
sp., Salmonella sp., Vibrio cholerae, E. coli, Klebsiella pneumoniae, Acinetobacter baumanii, 
Pseudomonas aeruginosa, some of these associated with the use of antimicrobials in 
animals grown for human food consumption in the 1980s and 1990s (Waterer and 
Wunderink, 2001; Rupp and Fey 2003; White  et al., 2001; Smith et al., 1999; Wegener, 
1999; Fey et al., 2000). Recently we have also witnessed the report of very worrisome 
cases of previously unthinkable resistance as well as the spread of resistant bacteria 
outside the hospital causing community-acquired infections. Such is the case or 
strains of Group A, Streptococcus becoming resistant to macrolide antibiotics 
(Seppala et al., 1995; Cizman et al., 2001; Martin et al., 2002; Huovinen, 2002), 
Streptococcus pneumoniae developing resistance to different antibiotic classes, 
including penicillin, and causing serious infections (Nuorti et al., 1998; Whitney et al., 
2000; Hofmann et al., 1995; Tomasz, 1995; Amsden, 2004; Vanderkooi et al., 2005; File, 
2004; Jacobs, 2004) and more virulent strains of MRSA (due to the expression of 
certain toxins such as the so-called Panton-Valentine leukocidin) spreading to the 
community (Saravolatz et al., 1982; Robinson et al., 2005; Kaplan et al., 2005), as well 
as Staphylococcus aureus and Enterococci becoming resistant to vancomycin (Smith et 
al., 1999; Sieradzki et al., 1999; Waldvogel, 1999).
The period of the late 1940s and early 1950s saw the discovery and introduction of 
streptomycin, chloramphenicol, and tetracycline, and the age of antibiotic 
chemotherapy came into full being. These antibiotics were effective against the full 
array of bacterial pathogens including gram-positive and gram-negative bacteria, 
intracellular parasites, and the tuberculosis bacillus. However, by 1953, during a 
Shigella outbreak in Japan, a strain of the dysentery bacillus was isolated, exhibiting 
resistances to chloramphenicol, tetracycline, streptomycin, and the sulfanilamides. 
There was also evidence mounting that bacteria could pass genes for multiple drug 
resistance between strains and even between species. 
Antibiotic resistance, initially a problem of the hospital setting associated with an 
increased number of hospital acquired infections usually in critically ill and 
immunosuppressed patients, has now extended into the community causing severe 
infections difficult to diagnose and treat. In hospitals, most common resistant 
bacteria include methicillin-resistant Staphylococcus aureus, vancomycin-resistant 
enterococci and gram-negative rods including Enterobacteriaceae and Pseudomonas 
aeruginosa. Gram-positive bacteria are common causes of bloodstream and other 
infections in hospitalized patients, and the percentage of nosocomial bloodstream 
infections caused by antibiotic-resistant gram-positive bacteria is increasing. 
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
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enterococci (VRE) are of particular concern. Vancomycin is the standard treatment 
for serious MRSA infections, but a few cases of vancomycin-resistant S. aureus 
(VRSA) have recently emerged, represent a new treatment challenge. More recently, 
community-acquired methicillin-resistant S. aureus (CA-MRSA) has become a 
problem in several countries causing skin infections but also severe diseases. 
Resistance to co-trimoxazole in Escherichia coli has changed empirical treatment of 
urinary tract infections. 
It was also apparent that Mycobacterium tuberculosis was capable of rapid 
development of resistance to streptomycin, which had become a mainstay in 
tuberculosis therapy. It is estimated that one third of the world’s population is 
infected with TB, with about 8 million new cases reported annually (National 
Institute of Allergy and Infectious Diseases (NIAID), Fact sheet on tuberculosis. 
www.niaid.nih.go.factsheets/tb.htm). India is one of the developing countries 
having TB and HIV infection on rise in an alarming speed. Still worse is the situation 
due to the emergence of multi-drug-resistant (MDR) strains of M. tuberculosis along 
with human immunodeficiency virus (HIV) infection. Moreover, secondary fugal 
infections that occur towards the later part of medication, among the TB patients 
aggravate the situation. In July 2003 report, the WHO has called TB (not AIDS) is the 
biggest health concern of India (Gupta, 2003). This reflects the magnitude and the 
seriousness of the problem. 
In recent times new mechanisms of resistance have resulted in the simultaneous 
development of resistance to several antibiotic classes creating very dangerous 
multidrug-resistant (MDR) bacterial strains, some also known as “superbugs”. The 
indiscriminate and inappropriate use of antibiotics in outpatient clinics, hospitalized 
patients and in the food industry is the single largest factor leading to antibiotic 
resistance. In recent years, the number of new antibiotics licensed for human use in 
different parts of the world has been lower than in the recent past. In addition, there 
has been less innovation in the field of antimicrobial discovery research and 
development. The pharmaceutical industry, large academic institutions or the 
government are not investing the necessary resources to produce the next generation 
of newer safe and effective antimicrobial drugs. In many cases, large pharmaceutical 
companies have terminated their anti-infective research programs altogether due to 
economic reasons. The potential negative consequences of all these events are 
relevant because they put society at risk for the spread of potentially serious MDR 
bacterial infections.
2. MECHANISMS OF RESISTANCE TO ANTIBACTERIAL AGENTS
Bacteria may manifest resistance to antibacterial drugs through a variety of 
mechanisms (Table 1). Of greater concern are cases of acquired resistance, where 
initially susceptible populations of bacteria become resistant to an antibacterial agent 
and proliferate and spread under the selective pressure of use of that agent. Several 
mechanisms of antimicrobial resistance are readily spread to a variety of bacterial 
genera-
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(1) The organism may acquire genes encoding enzymes, such as β-lactamases, 
that destroy the antibacterial agent before it can have an effect. 
(2) Bacteria may acquire efflux pumps that extrude the antibacterial agent from 
the cell before it can reach its target site and exert its effect. 
(3) Bacteria may acquire several genes for a metabolic pathway, which ultimately 
produces altered bacterial cell walls that no longer contain the binding site of 
the antimicrobial agent, or bacteria may acquire mutations that limit access of 
antimicrobial agents to the intracellular target site via down regulation of 
porin genes.
Thus, normally susceptible populations of bacteria may become resistant to 
antimicrobial agents through mutation and selection, or by acquiring from other 
bacteria the genetic information that encodes resistance. The last event may occur 
through one of several genetic mechanisms, including transformation, conjugation, 
or transduction. Through genetic exchange mechanisms, many bacteria have become 
resistant to multiple classes of antibacterial agents, and these bacteria with multidrug 
resistance have become a cause for serious concern, particularly in hospitals and 
other healthcare institutions where they tend to occur most commonly. As noted 
above, susceptible bacteria can acquire resistance to an antimicrobial agent via new 
mutations. Such spontaneous mutations may cause resistance by-
 altering the target protein to which the antibacterial agent binds by modifying 
or eliminating the binding site (e.g., change in penicillin-binding protein 2b in 
pneumococci, which results in penicillin resistance), 
 upregulating the production of enzymes that inactivate the antimicrobial agent 
(e.g., erythromycin ribosomal methylase in staphylococci),
 down regulating or altering an outer membrane protein channel that the drug 
requires for cell entry (e.g., OmpF in E coli), or upregulating pumps that expel 
the drug from the cell [efflux of fluoroquinolones in S. aureus (McManus, 1997)]. 
In all of these cases, strains of bacteria carrying resistance-conferring mutations 
are selected by antimicrobial use, which kills the susceptible strains but allows 
the newly resistant strains to survive and grow. 
Acquired resistance that develops due to chromosomal mutation and selection is 
termed vertical evolution. Vertical evolution is strictly a matter of Darwinian 
evolution driven by principles of natural selection: a spontaneous mutation in the 
bacterial chromosome imparts resistance to a member of the bacterial population. 
Bacteria also develop resistance through the acquisition of new genetic material from 
other resistant organisms. This is termed horizontal evolution, and may occur 
between strains of the same species or between different bacterial species or genera.
Bacteria are able to exchange genes in nature by three processes: conjugation, 
transduction and transformation (McManus, 1997). For each of these processes, 
transposons may facilitate the transfer and incorporation of the acquired resistance 
genes into the host’s genome or into plasmids. Conjugation: Conjugation is the most 
important and the most common mechanism of transmission of resistance in bacteria. 
During conjugation, a gram-negative bacterium transfers plasmid-containing 
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resistance genes to an adjacent bacterium, often via an elongated proteinaceous 
structure termed as pilus, which joins the two organisms. Conjugation among gram-
positive bacteria is usually initiated by production of sex pheromones by the mating 
pair, which facilitate the clumping of donor and recipient organisms, allowing the 
exchange of DNA. Transformation: Transformation is another form of transmission 
of bacterial resistance genes and takes place when there is direct passage of free DNA 
(also known as ‘‘naked DNA’’) from one cell to another. The ‘‘naked DNA’’ usually 
originates from other bacteria that have died and broken apart close to the receiving 
bacteria. The receiving bacteria then simply introduce the free DNA into their 
cytoplasm and incorporate it into their own DNA. Transduction: Transduction is a 
third mechanism of genetic transfer and occurs via the use of a ‘‘vector’’, most often 
viruses capable of infecting bacteria also known as ‘‘bacteriophages’’ (or simply 
‘‘phages’’). The virus containing the bacterial gene that codifies antibiotic resistance 
(the ‘‘resistant DNA’’) infects the new bacterial cell and introduces this genetic 
material into the receiving bacteria. Most times, the infecting bacteriophage also 
introduces to the receiving bacteria its own viral DNA, which then takes over the 
bacterial replication system forcing the cell to produce more copies of the infecting 
virus until the bacterial cell dies and liberates these new bacteriophages, which then 
go on to infect other cells.
Mutation and selection, together with the mechanisms of genetic exchange, enable 
many bacterial species to adapt quickly to the introduction of antibacterial agents 
into their environment. Genetic recombination can follow the transfer of DNA from 
one cell to another leading to the emergence of a new genotype (recombinant). It is 
common for DNA to be transferred as plasmids between mating bacteria. Since 
bacteria usually develop their genes for drug resistance on plasmids (called 
resistance transfer factors or RTFs), they are able to spread drug resistance to other 
strains and species during genetic exchange processes. 
2.1 Biological Mechanisms of Resistance
Whichever way a gene is transferred to a bacterium, the development of antibiotic 
resistance occurs when the gene is able to express itself and produce a tangible 
biological effect resulting in the loss of activity of the antibiotic. These biological 
mechanisms are many and varied but they can be summarized as follows. 
2.1.1 Antibiotic Destruction or Antibiotic Transformation
This destruction or transformation occurs when the bacteria produces one or more 
enzymes that chemically degrade or modify the antimicrobial making them inactive 
against the bacteria. This is a common mechanism of resistance and probably one of 
the oldest ones affecting several antibiotics but especially b-lactam antibiotics via the 
bacterial production of β-lactamases (Jacoby and Munoz-Price, 2005). 
2.1.2 Antibiotic Active Efflux
Efflux was first described for tetracycline and macrolide antibiotics (Roberts, 1996; 
Leclercq, 2002) but is now common for many other antibiotics such as 
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fluoroquinolones (Sefton, 2002; Hooper, 2005). Antibiotic active efflux is relevant for 
antibiotics that act inside the bacteria and takes place when the microorganism is 
capable of developing an active transport mechanism that pumps the antibiotic 
molecules that penetrated into the cell to the outside milieu until it reaches a 
concentration below that necessary for the antibiotic to have antibacterial activity. 
This means that the efflux transport mechanism must be stronger than the influx 
mechanism in order to be effective (Hooper, 2005). 
2.2 Receptor Modification
Receptor modification occurs when the intracellular target or receptor of the 
antibiotic drug is altered by the bacteria, resulting in the lack of binding and 
consequently the lack of antibacterial effect. Examples of this mechanism include 
modifications in the structural conformation of penicillin-binding proteins (PBPs) 
observed in certain types of penicillin resistance, ribosomal alterations that can 
render aminoglycosides, macrolides or tetracyclines inactive, and DNA-gyrase 
modifications resulting in resistance to fluoroquinolones (Levy and Marshall, 2004; 
Sefton, 2002). It is likely that more and newer biological mechanisms of resistance 
will develop in the future. 
TABLE 1. Mechanisms of resistance
Mechanism Class of antibiotic
1. Reduced uptake into cell Chloramphenicol, β-lactams
2. Active efflux from cell Tetracycline, Quinolones
Sulfonamides, Trimethoprim
3. Modification of target to eliminate or reduce 
binding of   antibiotic
β-lactams, Erythromycin
Rifampicin, minoglycosides
4. Detoxification of antibiotic by enzyme 
modification:
i. Hydrolysis
ii. derivatization
β-lactams, Erythromycin
Aminoglycosides, 
Chloramphenicol
Fosfomycin, Lincomycin
5. Sequestration of antibiotic by protein binding β-lactams, Fusidic acid
6. Metabolic bypass of inhibited reaction Sulfonamides, Trimethoprim
7. Binding of specific immunity protein to 
antibiotic
Bleomycin
8. Overproduction of antibiotic target (titration) Sulfonamides, Trimethoprim
9. Failure to active prodrug Isoniazid
3. MECHANISMS OF ACTION OF ANTIBACTERIAL AGENTS
Most antimicrobial agents used for the treatment of bacterial infections may be categorized 
according to their principal mechanism of action. There are 4 major modes of action (Table 
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2): (1) interference with cell wall synthesis, (2) inhibition of protein synthesis, (3) interference 
with nucleic acid synthesis, and (4) inhibition of a metabolic pathway (Neu, 1992).
Antibacterial drugs that work by inhibiting bacterial cell wall synthesis include the β-
lactams, such as the penicillins, cephalosporins, carbapenems, and monobactams, and the 
glycopeptides, including vancomycin and teicoplanin (Neu, 1992; McManus, 1997). β-Lactam 
agents inhibit synthesis of the bacterial cell wall by interfering with the enzymes required for 
the synthesis of the peptidoglycan layer (McManus, 1997). Vancomycin and teicoplanin also 
interfere with cell wall synthesis, but do so by binding to the terminal D-alanine residues of 
the nascent peptidoglycan chain, thereby preventing the cross-linking steps required for 
stable cell wall synthesis (McManus, 1997). Macrolides, aminoglycosides, tetracyclines, 
chloramphenicol, streptogramins, and oxazolidinones produce their antibacterial effects by 
inhibiting protein synthesis (McManus, 1997). Bacterial ribosomes differ in structure from 
their counterparts in eukaryotic cells. Antibacterial agents take advantage of these 
differences to selectively inhibit bacterial growth. Macrolides, aminoglycosides, and 
tetracyclines bind to the 30S subunit of the ribosome, whereas chloramphenicol binds to the 
50S subunit. Fluoroquinolones exert their antibacterial effects by disrupting DNA synthesis 
and causing lethal double-strand DNA breaks during DNA replication, (Drlica and Zhao,  
1997) whereas sulfonamides and trimethoprim (TMP) block the pathway for folic acid 
synthesis, which ultimately inhibits DNA synthesis (Yao and Moellering, 2003; Petri, 2006).
The common antibacterial drug combination of TMP, a folic acid analogue, plus 
sulfamethoxazole (SMX) (a sulfonamide) inhibits 2 steps in the enzymatic pathway for 
bacterial folate synthesis. Disruption of bacterial membrane structure may be a fifth, 
although less well characterized, mechanism of action. It is postulated that polymyxins exert 
their inhibitory effects by increasing bacterial membrane permeability, causing leakage of 
bacterial contents (Storm, 1977). The cyclic lipopeptide daptomycin apparently inserts its 
lipid tail into the bacterial cell membrane, (Carpenter and Chambers, 2004) causing 
membrane depolarization and eventual death of the bacterium.
TABLE 2. Mechanisms of action of antibacterial agents
Mechanisms Antibiotic class
Interference with cell wall synthesis β-Lactams: penicillins, cephalosporins, 
carbapenems, monobactams
Glycopeptides: vancomycin, teicoplanin
Protein synthesis inhibition
Bind to 50S ribosomal subunit 
Bind to 30S ribosomal subunit 
Bind to bacterial isoleucyl-tRNA synthetase
macrolides, chloramphenicol, clindamycin, 
quinupristin-dalfopristin, linezolid
aminoglycosides, tetracyclines
mupirocin
Interference with nucleic acid synthesis
Inhibit DNA synthesis
Inhibit RNA synthesis 
fluoroquinolones
rifampin
Inhibition of metabolic pathway sulfonamides, folic acid analogues
Disruption of bacterial membrane structure polymyxins, daptomycin
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4. ANTIMICROBIAL RESISTANCE IN GRAM-POSITIVE BACTERIA
Gram-positive bacteria—particularly gram-positive cocci like coagulase-negative 
staphylococci, Staphylococcus aureus, and Enterococcus spp—are extremely important 
pathogens in the hospital environment. Data from the Surveillance and Control of 
Pathogens of Epidemiologic Importance (SCOPE) project, which monitors significant 
bloodstream infections in hospitalized patients in the United States, indicated that 
60% of nosocomial bloodstream infections for the 3-year period from April 1995 
through April 1998 involved gram-positive bacteria (Edmond et al., 1999). Coagulase-
negative staphylococci were the causes of 31.9% of monomicrobial nosocomial 
bloodstream infections, followed by S. aureus in 15.7 %, enterococci species in 11.1%, 
and viridans streptococci in 1%. Updated figures from the SCOPE project covering 
March, 1995 through September, 2002 revealed similar findings (Wisplinghoff et al., 
2004). Increasing resistance in gram-positive bacteria can be expected to complicate 
treatment and potentially lead to increased morbidity and mortality. 
4.1 Methicillin-resistant S. aureus
The first of these problematic bacteria was S. aureus. Virtually all S. aureus strains 
were susceptible to penicillin G when the latter was initially introduced in the early 
1940s, but by 1944 the first reports of penicillin-resistant S. aureus had already 
appeared, and today virtually all strains of S. aureus are resistant to natural 
penicillins, aminopenicillins, and antipseudomonal penicillins (Chambers, 2001; Neu, 
1992). Resistance to these drugs occurs because of the acquisition of genes that 
encode drug-inactivating enzymes, initially known as penicillinases and now called 
β-lactamases. At first, cases of penicillin resistant S. aureus were limited and 
appeared only in healthcare settings, but over time resistant species were observed 
and became increasingly prevalent in the wider community as well (Chambers, 
2001). Methicillin and other penicillinase-resistant penicillins were developed to treat 
infections caused by penicillin-resistant S. aureus and met with initial success. MRSA 
is currently recognized as a major problem in hospitals and the broader community 
in the United States and throughout the world (Diekema et al., 2001). The most recent 
SCOPE project report showed that methicillin resistance was present in 44% of S.
aureus bloodstream isolates from ICU infections (Wisplinghoff  et al., 2004).
Methicillin was introduced in 1959 to treat infections caused by penicillin-resistant 
Staphylococcus aureus. In 1961, there were reports from the United Kingdom of S. 
aureus isolates that had acquired resistance to methicillin (methicillin-resistant S. 
aureus, MRSA) (Jevons, 1961), and MRSA isolates were soon recovered from other 
European countries, and later from Japan, Australia (Palavecino, 2004). The 
acquisition of methicillin resistance gave these bacteria the name methicillin-resistant 
S. aureus (MRSA), but in reality these were multidrug-resistant S. aureus (Wadsworth 
et al., 1992). MRSA is now a problem in hospitals worldwide and is increasingly 
recovered from nursing homes and the community (Hussain et al., 2000). Periodic 
outbreaks of MRSA were observed in various countries throughout the 1970s and 
were typically associated with high methicillin use in intensive care units 
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(Palavecino, 2004), but it was not until the 1980s that MRSA began to become a really 
significant problem in United States hospitals—first in hospitals with a large number 
of beds and then in community hospitals (Panlilio et al., 1992).  
The methicillin resistance gene (mecA) encodes a methicillin-resistant penicillin-
binding protein that is not present in susceptible strains and is believed to have been 
acquired from a distantly related species (Hiramatsu et al., 2001). Expression of the 
mecA gene encoding low-affinity penicillin-binding protein PBP2a confers resistance 
to other β-lactams in addition to methicillin (Utsui and Yokota, 1985), but the 
resistance pattern of MRSA typically includes other classes of antibiotics as well.
Nosocomial MRSA is remarkable for its clonal pattern of spread. A recent study 
looking at 359 MRSA isolates collected from 20 countries from 1961 to 1999 identified 
11 major MRSA clones within 5 groups of related genotypes (Enright et al., 2002).
Results from a recent study in the United Kingdom examining a new epidemic strain 
of MRSA, designated EMRSA-17, illustrate multidrug resistance (Aucken et al., 2002).
EMRSA-17 expressed resistance to methicillin, fluoroquinolones (ciprofloxacin), 
macrolides (erythromycin), aminoglycosides (gentamicin, kanamycin, neomycin, and 
streptomycin), tetracycline, rifampin, and fusidic acid. Virtually all variants of this 
strain were multidrug resistant. In particular, fluoroquinolone resistance is a 
hallmark of nosocomial MRSA, although this was not always the case. When 
ciprofloxacin was first introduced, it was recommended as the first orally 
administered treatment effective against MRSA. However, within one year many 
hospitals observed dramatic increases in the rate of ciprofloxacin resistance in MRSA. 
High-level ciprofloxacin resistance was observed within 3 months of ciprofloxacin 
introduction, and within one year, 79% of all MRSA from hospitalized patients 
exhibited resistance (Blumberg et al., 1991). For many years, vancomycin was the 
only effective treatment for serious MRSA infections. But in the past 4 years, 4 new 
agents with anti-MRSA activity have been introduced (quinupristin-dalfopristin, 
linezolid, daptomycin, and tigecycline). These new agents are most welcome, since 
the past decade has seen the emergence of vancomycin resistance in S. aureus. S. 
aureus with intermediate resistance to vancomycin (vancomycin-intermediate S.
aureus [VISA]; minimum inhibitory concentration [MIC], 8 to 16 mg/L) was first 
observed in 1996 in a strain isolated from a hospitalized patient in Japan (Hiramatsu 
et al., 1997). The mechanism of resistance in VISA has been linked to cell wall 
thickening, which may cause vancomycin molecules to become trapped in the outer 
layers of the cell wall, thereby limiting access to the cytoplasmic membrane where 
the functional targets of vancomycin are located (Cui et al., 2003). The mechanism for 
this high-level vancomycin resistance involves the horizontal transfer of a transposon 
containing vanA and associated genes from VRE (Rice, 2006).
Many studies have characterized MRSA isolates from individual hospitals or 
countries and have identified strains that appear to be well adapted to the hospital 
environment, are established in several hospitals within a country, or have spread 
internationally (epidemic MRSA, EMRSA). MRSA isolates are generally 
characterized by pulsed-field gel electrophoresis, a powerful technique for 
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identifying the relatedness of isolates from recent outbreaks within a hospital, but are 
not well suited to long-term global epidemiology, which requires a procedure that is 
highly discriminatory but that indexes variation that accumulates slowly. Multilocus 
sequence typing (MLST) provides such a procedure and characterizes isolates of 
bacteria unambiguously by using the sequences of internal fragments of seven 
housekeeping genes (Enright and Spratt, 1999). MLST has been developed and 
validated for S. aureus (Enright et al., 2000), and provides a discriminatory method 
that allows related strains recovered in different countries to be readily identified. 
The origins of the major MRSA clones are still poorly understood. Kreiswirth et al. 
(1993) proposed that all MRSAs were descended from a single ancestral S. aureus 
strain that acquired mecA, but more recent studies (Musser and Kapur, 1992) show 
that some MRSAs are very divergent, implying that mecA has been transferred 
between S. aureus lineages.
4.2 Multidrug-Resistant (MRD) Enterococcal Species
Enterococcus faecalis and E. faecium are species normally found in human gut flora 
and, apart from their rare occurrence as the cause of urinary tract infections, they 
were not usually considered as pathogenic. However, when patients were given 
immunosuppressive therapy, enterococci were increasingly found as the causative 
organism of infection. Like MRSA, the final defense against these gram-positive 
bacteria was considered to be vancomycin, but, by the end of the 1980s, they had 
acquired the ability to resist high levels of vancomycin (Woodford et al., 1993). 
Despite the fact that vancomycin has been in clinical use since the late 1950s, VRE 
were not observed until the mid-1980s, and in the United States, VRE were virtually 
non-existent as recently as 1989 (Martone, 1998). During the 1990s, however, a 
dramatic rise in VRE occurred—first in Intensive Care Units (ICUs), then essentially 
throughout hospitals. The latest NNIS report indicated that nearly 30% of all 
enterococci isolated from patients infected in ICUs are now resistant to vancomycin.
Perhaps an even more remarkable aspect of this outbreak is the fact that an 
overwhelming majority of VRE are Enterococcus faecium. The Surveillance Network 
Database –USA showed that resistance to both vancomycin and ampicillin was much 
more prevalent among E. faecium than among Enterococcus faecalis in patients with 
nosocomial bloodstream infections in 1995 and 1997 (Sahm et al., 1999).
The mechanism of vancomycin resistance is particularly sophisticated and, 
although there are different variations of it, they all involve the reversal of the 
bacterium’s normal manufacture of the cell wall. This is accompanied by the 
synthesis of a modified cell wall, which includes D-alanyl-D-lactate, or D-alanyl-D-
serine terminal dipeptides, which are less capable of binding vancomycin than the 
normal bacterial dipeptide D-alanyl-D-alanine (Arthur et al., 1996). Vancomycin 
resistance is mediated by either of 2 classes of related gene clusters: one class 
contains vanA and other class contains vanB (Arthur et al., 1996). Both produce 
resistance by altering the target for vancomycin from D-alanine-D-alanine to D-
alanine- D-lactate.
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5. ANTIMICROBIAL RESISTANCE IN GRAM-NEGATIVE BACTERIA
Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae are among 
the bacteria that readily develop multiple resistance mechanisms to various classes of 
antibiotics (Hanlon, 2005; Helfand and Bonomo, 2005; McGowan Jr, 2006; Ramphal 
and Ambrose, 2006; Rossolini and Mantengoli, 2005). In addition, they are important 
nosocomial pathogens affecting both immunocompetent and immunocompromised 
patients and are responsible for a considerable proportion of infections in patients in 
ICUs worldwide. Thus, infections by multidrug-resistant (MDR) P. aeruginosa, A. 
baumannii and K. pneumoniae strains have become common in healthcare institutions. 
The continuously evolving resistance to antibiotics of P. aeruginosa, A. baumannii and 
K. pneumoniae has led to the emergence of clinical isolates susceptible to only one 
class of antimicrobial agents and eventually to pandrug-resistant (PDR) isolates, i.e. 
resistant to all available antibiotics (Kuo et al., 2004; Marais et al., 2004; Yoon et al., 
2004). Polymyxins, an old class of polypeptide cationic antibiotic that was abandoned 
during the 1980s and 1990s in most parts of the world, have been used as the last 
class of available antibiotics to which some of these bacterial isolates were susceptible 
in vitro. Several recent clinical studies have reported on the therapeutic use of 
polymyxins in patients with infections by organisms with such a phenotype (i.e. 
susceptible only to polymyxins) Garnacho-Montero et al., 2003; Michalopoulos et al., 
2005; Falagas et al., 2006; Levin et al., 1999). In addition, there have been some recent 
clinical studies that reported on infections with isolates of P. aeruginosa, A. baumannii 
and K. pneumoniae that were characterized as PDR. However, in some of these studies 
either the isolates were not tested in vitro against polymyxins or they were tested and 
found to be susceptible to them (Kuo et al., 2004; Marais et al., 2004). PDR infections 
due to the aforementioned gram-negative bacteria represent a fearful clinical 
situation with tremendous public health implications in which the clinician is left 
with practically no rational choice of antibiotic treatment. Thus, data regarding the 
frequency of PDR clinical isolates, the morbidity and mortality related to infections 
by these isolates and the therapeutic options, if any, are of great clinical and public 
health importance. 
6. STRATEGIES FOR REDUCING THE IMPACT OF RESISTANCE
Antibiotic resistance is driven by antibiotic use. When antibiotics are superseded 
and therefore used less, strains resistant to these tend to disappear. 
6.1. In the Community
In the UK, more than 80% of human use of antibiotics occurs in the community, 
mostly for respiratory tract infections. The Standing Medical Advisory Committee, in 
its report The Path of Least Resistance, made recommendations to reduce inappropriate 
prescribing (Standing Medical Advisory Committee, Department of Health. The path 
of least resistance. London: HMSO, 1998).
 No antibiotics should be given for simple coughs and colds.
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 Antibiotics should not be routinely prescribed for sore throats, unless there is 
evidence of streptococcal infection.
 Antibiotics are not routinely required for acute otitis media and sinusitis-like 
symptoms; if given, courses can be limited to 3 days. In addition, 3 days’ 
treatment should suffice in otherwise healthy women with uncomplicated 
cystitis. This strategy has been useful in reducing prescribing by GPs, but anxiety 
has resulted from anecdotal reports of an increase in bacterial respiratory 
infections. In hospital, antibiotic use can be reduced by several means.
 Routine use of antibiotics for surgical prophylaxis should be reduced to a 
minimum.
 Antibiotics should not be started immediately in all suspected infections. Certain 
patients (e.g. those with febrile neutropenia or evidence of septicaemia) require 
urgent antibiotic therapy, but in many other cases (e.g. mild pyrexia 
postoperatively), it is safe and ultimately preferable to withhold antibiotics until 
culture results are known or there is clear evidence of bacterial infection.
 An alternative is to discontinue antibiotics as soon as information is available 
suggesting that the problem is not bacterial or has resolved itself. This is termed 
an ‘antibiotic-stop’ policy, and the aim is to encourage doctors to actively review 
the need for antibiotics after, say, the second day, given information on cultures 
and surrogate markers that has by then become available.
 Certain antibiotics can be withheld from the hospital formulary. This is the main 
benefit of an agreed antibiotic policy. The choice of restricted antibiotics may be 
decided on the basis of cost rather than likely selection of resistance (these 
antibiotics must be used occasionally, however, when resistance to all other 
available drugs has been selected).
 In theory, antibiotics can be rotated such that, for example, predominantly 
penicillins are used at some times, and cephalosporins or quinolones at others. 
There is little clear scientific evidence that this has any effect, and major, 
complicated studies would be needed to determine the effect of change in use on 
both normal and infecting flora. However, it has been shown that, in a setting of 
heavy cephalosporin use, discontinuation of use of this class of drugs leads to a 
reduction in the risk of colonization with glycopeptide-resistant enterococci and 
Clostridium difficile associated diarrhoea. 
6.2 Other Strategies:
Development of resistance in human pathogens might be delayed if antibiotics 
were not used so widely in animal husbandry, particularly for growth promotion. 
7. THE FUTURE
Resistance to antibiotics is one of the greatest threats to the success of modern 
medicine. It has recently become more serious because we can no longer be sure that 
any antibiotic chosen empirically will work, and because of the emergence of totally 
resistant bacteria. How to reduce resistance without simply discontinuing use of all 
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antibiotics is a dilemma. We do not know to what degree antibiotic use must be 
reduced to decrease the selective pressure and allow reversion to sensitivity, nor do 
we know how to protect the few remaining drugs that can be used to treat resistant 
infections. Doctors and vets should overcome the view that they have an inalienable 
right to prescribe empirical antibiotics, and should set targets for reduction of their 
personal prescribing.
8. NOVEL AGENTS FOR RESISTANT BACTERIAL INFECTIONS
Emerging bacterial resistance to many available antimicrobial agents has led to a 
recent surge of pharmaceutical development, which has resulted in production of 
several new antibiotics. Novel agents, almost all derivatives of old compounds, have 
recently been introduced into clinical practice.
8.1 Linezolid
The oxazolidinones are a unique family of antimicrobial agents, first developed in 
the late 1970s for agricultural use (Brickner et al., 1996). The agents are effective 
against a wide range of gram-positive bacteria, anaerobes and Mycobacterium 
tuberculosis. Linezolid was the first derivative with acceptable tolerability in man to 
advance to clinical trials, and is the first Federal Drug Administration approved 
oxazolidinone for the treatment of pneumonia and skin and soft tissue infections 
caused by susceptible organisms, and infections caused by VRE. It has not yet been 
approved for the treatment of penicillin-resistant Streptococcus pneumoniae
(Cammarata et al., 2000).
Linezolid possesses activity against staphylococci, including Staphylococcus aureus, 
irrespective of its oxacillin susceptibility (Cercenado, 2001; Gemmell, 2001), and 
against the recently isolated glycopeptide-intermediately-resistant S. aureus (GISA) 
(Rybak, 2000). Linezolid is active against glycopeptide resistant coagulase-negative 
staphylococci (Cercenado, 2001). In addition, activity against other major multidrug-
resistant Gram positive pathogens, including VRE and penicillin resistant 
Streptococcus pneumoniae has also been demonstrated, independent of their 
resistance profile to other antibacterials (Jones et al., 1999; Noskin et al., 1999). 
8.2 Daptomycin
Daptomycin is the first in a new class of cyclic lipopeptide drugs derived from the 
fermentation of Streptomyces roseosporus. It was first discovered in the 1980s and was 
shown to be effective in the treatment of skin and soft tissue infection (SSTI). 
However, because of muscle toxicity, which appeared at higher doses as used in the 
treatment of endovascular infections and endocarditis, and because of clinical 
failures (Garrison et al., 1989) clinical trials were suspended. The emergence of 
infections caused by resistant gram positive bacteria led in 1997 to renewed interest 
in daptomycin, with new data obtained in the laboratory and in animal and human 
studies.
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Daptomycin is active solely against gram-positive bacteria. Daptomycin was also 
active against betahaemolytic streptococci, viridans streptococci, as well as against 
gram-positive rods such as Leuconostoc, which are characteristically resistant to 
glycopeptides (Jones and Barry 1987; Barry, 2001; King and Phillips 2001). The effect 
of calcium in the medium was especially evident when enterococcal susceptibility 
was evaluated. Daptomycin was active against most strains, including VRE. 
However, added calcium increased the activity of daptomycin two- to fourfold 
(Barry, 2001; King and Phillips 2001). Unlike most other antibiotics, which are only 
bacteriostatic against enterococci, daptomycin exhibits rapid, concentration 
dependent bactericidal activity against these pathogens, as well as against other 
bacteria (Snydman, 2001). 
8.3 GAR-936
Tetracyclines have been important broad-spectrum antimicrobial agents for the last 
40 years. In order to overcome resistance to these drugs, modification of their 
structures was undertaken. Glycylcyclines are obtained by modification of the 9-
position of chlortertracycline, minocycline, or doxycycline. GAR-936 is a novel 
derivative of minocycline, active against tetracycline-resistant organisms (Sum and 
Petersen, 1999)
GAR-936 is generally less active than its parent compound against minocycline 
sensitive, oxacillin susceptible and -resistant staphylococci, but it does show in vitro
activity against minocycline-resistant strains of Staphylococcus aureus and CONS. 
However, mean MIC against these isolates is higher than the MIC against the 
susceptible strains (Boucher, 2000; Petersen, 1999). 
The activity against aerobic gram-negative rods is fair. Many enterobacteriaceae, 
including Escherichia coli were inhibited by GAR-936 (Proteus spp. excluded). 
However, other strains were resistant, with the potency of other antibiotics, 
including ciprofloxacin, ceftazidime and imipenem, being significantly better 
(Petersen, 1999; van Ogtrop, 2000). In addition, GAR-936 retains its activity against 
some nonfermentative bacteria such as Stenotrophomonas maltophilia, although it is not 
active against P. aeruginosa (van Ogtrop, 2000; Gales and Jones, 2000). 
Most strains of Neisseria gonorrhoeae are susceptible to GAR-936, including 
penicillin- or tetracycline resistant strains (Whittington, 1995). In addition, GAR-936 
is highly active against other sexually transmitted diseases pathogens, including 
Chlamydia trachomatis (Roblin and Hammerschlag, 2000), as well as against 
Mycoplasma spp. and Ureaplasma urealyticum (Kenny GE, Cartwright, 2001). 
8.4 LY-333328 (Oritavancin)
Vancomycin was introduced in 1956 because of its effectiveness against penicillin-
resistant staphylococci. Approximately 30-years later, acquired glycopeptide 
resistance in Enterococcus spp. was reported followed by clinical isolates of GISA in 
1997 (Fekety, 2000). However, to overcome resistance, vancomycin derivatives that 
has hydrophobic substituents on the vancosamine nitrogen have been developed. 
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LY-264826 is a naturally occurring glycopeptide with the same core structure as 
vancomycin but with differences in associated sugars present. Alkyl modification of 
the disaccharide amino led to several compounds, the most active of which is LY-
333328 (Nicas et al., 1996).
LY-333328 proved effective against the major multi-drug-resistant gram-positive 
bacteria (Zeckel et al., 2000). LY-333328 was equally effective against oxacillin 
susceptible and methicillin-resistant Staphylococcus aureus (MRSA). However, its 
activity for most strains was either identical or less efficient than other glycopeptides 
(vancomycin and teicoplanin) (Zeckel et al., 2000; Biavasco, 1997). LY-333328 
possesses good in vitro activity against Enterococcal spp., including glycopeptide-
resistant strains of the three major phenotypes (VanA, VanB, and VanC), with MICs 
significantly lower than the other glycopeptides (Zeckel et al., 2000; Garcia-Garrote et 
al., 1998; Biavasco et al., 1997; Fraise et al., 1997).
9. CONCLUSION 
Development of new antibiotics has not kept pace with the emergence of antibiotic 
resistance. In the past few decades, pharmaceutical companies have shifted their 
developmental efforts to drugs for chronic diseases such as heart diseases and high 
blood pressure and anti-viral instead of antibiotics. The steady increase in resistant 
organisms is related to the widespread use of antibiotics in community and hospital 
settings. New therapeutic options are needed, including treatments for infections 
caused by antibiotic-resistant gram-positive organisms. Moreover, resurgence of TB 
in an epidemic form due to HIV infection especially in both developed and 
underdeveloped countries together with the development of multi-drug resistant 
strains among the patients have assumed a serious situation in health care sector. 
Now, the only answer is to search for novel and effective drug regime to fight this 
menace. 
Today, intensive programmes seeking for antibiotics are running worldwide. In our 
laboratory (NEIST, formerly RRL (CSIR), Jorhat, India), mainly, by screening soils 
and water, and testing the activity of the isolated organisms against specific 
pathogenic bacteria or fungi that are resistant to several known antibiotics. In our 
laboratory, a bacterial strain, namely, Streptomyces sp. 201 was isolated from the tea 
garden soil of Jorhat, Assam, India, (26.44 N and 94.10 E) exhibited promising anti-
fungal and anti-bacterial activity against a wide range of pathogens including M. 
tuberculosis (Bordoloi et al., 2001; Bordoloi et al., 2002). Absolute stereochemistry of 
the new antifungal and antibacterial antibiotic produced by Streptomyces sp.201 has 
been established by achieving the total synthesis of the product (Boruwa et al., 2004). 
The vast resources of microorganisms have received increasing attention from 
chemists and pharmacologists and played an important role in the explosive growth 
of biomedical science during the past two decades. The recent advent of 
sophisticated chromatographic (HPLC, gel filtration etc.), high field NMR and mass 
spectroscopic techniques coupled with force field calculations and X-ray 
crystallography have markedly enhanced the isolation and structure elucidation of 
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more complex and diverse natural products and along with advanced bioassay 
methods has opened new possibilities in discovery of drugs and agrochemicals from 
natural sources. 
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